Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

This research is an essential source of information and analysis on the global Myasthenia Gravis Therapeutics market. The report identifies the key trends shaping and driving the global Myasthenia Gravis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Myasthenia Gravis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Myasthenia Gravis Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Myasthenia Gravis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Myasthenia Gravis Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Myasthenia Gravis Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Myasthenia Gravis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Myasthenia Gravis Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Myasthenia Gravis Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Myasthenia Gravis Therapeutics market landscape? – Identify, understand and capitalize.

Companies Mentioned:

• Cytokinetics, Inc.
• Alexion Pharmaceuticals, Inc

Additional Information:

Myasthenia Gravis Therapeutics Market is Forecast to Show Slow Growth Until 2019

GlobalData estimates that the global myasthenia gravis therapeutics market was worth $62.9m in 2011. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.9% over the next eight years to reach $92.2m by 2019. The growth in this market can be attributed to an increase in the myasthenia gravis prevalent population. The increase in the prevalent population is primarily due to a reduction in the mortality rate and the longer life expectancy of myasthenia gravis patients. Although the number of treated patients is increasing, the market is experiencing slow growth due to a lack of efficacious products that can treat the disease as opposed to providing symptomatic relief. The treatment landscape is not going to see any major change in the forecast period due to the lack of promising molecules in the late stage pipeline. The global myasthenia gravis market is expected to remain a low value market during the forecast period due to the domination of generics and off-label drugs.

Current Treatment Options Leave a High Level of Unmet Need

GlobalData`s research indicates that the current treatment options are focused on offering symptomatic relief as opposed to treating the disease. The current treatment landscape consists of acetylcholine esterase (AChE) inhibitors (pyridostigmine bromide), steroid (prednisone) and immunosupressants such as azathioprine, cyclosporin A, and mycophenolate mofetil. The available treatment options are moderately successful in meeting the market demand. Even though the mortality rate has declined significantly after the introduction of these drugs, patient satisfaction is still low as the therapies only target symptoms of the disease. This is the reason for the high unmet need in the myasthenia gravis therapeutics market.

The Current Pipeline is Weak and No New Molecules with Novel Mechanisms of Action are Expected to Enter the Market During the Forecast Period (2011-2019)

GlobalData’s analysis shows that the current myasthenia gravis therapeutics pipeline is weak. The myasthenia gravis therapeutics pipeline consists of six molecules in the various stages of development.

Phase III contains one molecule, four molecules are in Phase II and one molecule is in the IND filed stage. The late stage pipeline contains only one molecule (prednisone) which is already used as an off label drug for the treatment of myasthenia gravis. The early stage pipeline seems promising, but these drugs are in the early stages of development and will not have an impact on the myasthenia gravis therapeutics market during the forecast period.

Table of Contents

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6

2 Myasthenia Gravis Therapeutics - Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 8
2.3 Etiology and Pathology 10
2.4 Signs and Symptoms 12
2.5 Diagnosis 12
2.5.1 Pharmacological Testing - There are two types of pharmacological tests 12
2.5.2 Serological Testing: 12
2.5.3 Electrophysiological Testing: 13
2.5.4 Imaging Tests: 13
2.6 Treatment and Management Pattern 14
2.6.1 Pharmacological Therapy 14
2.7 Referral Pathway 15
2.8 GlobalData Pipeline Report Guidance 16

3 Myasthenia Gravis Therapeutics - Market Characterization 17
3.1 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Global 17
3.2 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Global 18
3.3 Myasthenia Gravis Therapeutics Market Size (2006-2011) - The US 19
3.4 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - The US 20
3.5 Myasthenia Gravis Therapeutics Market Size (2006-2011) - France 21
3.6 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - France 22
3.7 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Germany 23
3.8 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Germany 24
3.9 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Italy 25
3.10 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Italy 26
3.11 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Spain 27
3.12 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Spain 28
3.13 Myasthenia Gravis Therapeutics Market Size (2006-2011) - The UK 29
3.14 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - The UK 30
3.15 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Japan 31
3.16 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Japan 32
3.17 Drivers and Barriers for the Myasthenia Gravis Therapeutics Market 33
3.17.1 Drivers for the Myasthenia Gravis Therapeutics Market 33
3.17.2 Barriers for the Myasthenia Gravis Therapeutics Market 33
3.17.3 Opportunity and Unmet Need Analysis 33
3.18 Key Takeaway 34

4 Myasthenia Gravis Therapeutics - Competitive Assessment 35
4.1 Overview 35
4.2 Strategic Competitor Assessment 35
4.3 Product Profiles of the Major Marketed Products in the Myasthenia Gravis Therapeutics Market 37
4.3.1 Acetylcholinesterase Inhibitor (pyridostigmine) 37
4.3.2 Steroids (prednisone) 38
4.3.3 Immunosuppressants 38
4.3.4 Azathioprine 38
4.3.5 Cyclosporin A 39
4.3.6 Mycophenolate Mofetil (MMF) 39
4.3.7 Venoglobulin-IH 40
4.4 Key Takeaway 40

5 Myasthenia Gravis Therapeutics - Pipeline Assessment 41
5.1 Overview 41
5.2 Strategic Pipeline Assessment 41
5.3 Myasthenia Gravis Therapeutics Pipeline - Pipeline by Phases of Development 41
5.3.1 Myasthenia Gravis Therapeutics - Phase III Pipeline 41
5.3.2 Myasthenia Gravis Therapeutics - Phase II Pipeline 42
5.3.3 Myasthenia Gravis Therapeutics - IND filed Pipeline 42
5.3.4 Technology Trends Analytic Framework 42
5.4 Myasthenia Gravis Therapeutics Market -Pipeline by Mechanism of Action 44
5.5 Myasthenia Gravis Therapeutics - Promising Drugs under Clinical Development 45
5.6 Molecule Profile for Promising Drugs under Clinical Development 45
5.7 Key Takeaway 45

6 Myasthenia Gravis Therapeutics - Clinical Trials Mapping 46
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 46
6.2 Clinical Trials by Phase 47
6.3 Clinical Trials by Trial Status 48
6.4 Prominent Sponsors 49
6.5 Top Companies Participating in Myasthenia Gravis Therapeutics Clinical Trials 51

7 Strategic Assessment 52
7.1 Key Events Impacting the Future Market 52
7.2 Myasthenia gravis Therapeutics: Implications for Future Market Competition 53

8 Myasthenia Gravis Therapeutics - Future Players 54
8.1 Company Profiles 54
8.2 Cytokinetics, Inc. 54
8.3 Alexion Pharmaceuticals, Inc 55

9 Myasthenia Gravis Therapeutics - Licensing and Partnership Deals 56

10 Myasthenia Gravis Therapeutics - Appendix 57
10.1 Market Definitions 57
10.2 Abbreviations 57
10.3 Methodology 57
10.3.1 Coverage 58
10.3.2 Secondary Research 58
10.3.3 Forecasting 58
10.3.4 Primary Research 60
10.3.5 Expert Panel Validation 61
10.4 Contact Us 61
10.5 Disclaimer 61
10.6 Bibliography 61

List of Tables

Table 1:   Clinical Classification of Myasthenia Gravis According to Myasthenia Gravis Foundation of America (MGFA) 7
Table 2: Prevalence of Myasthenia Gravis by Country (G7) 8
Table 3: Myasthenia Gravis Quality of Life Questionnaire 9
Table 4: Myasthenia Gravis Therapeutics Market, Global, Revenue ($m), 2006-2011 17
Table 5: Myasthenia Gravis Therapeutics Market, Global, Forecast ($m), 2011-2019 18
Table 6: Myasthenia Gravis Therapeutics Market, The US, Revenue ($m), 2006-2011 19
Table 7: Myasthenia Gravis Therapeutics Market, The US, Forecasts ($m), 2011-2019 20
Table 8: Myasthenia Gravis Therapeutics Market, France, Revenue ($m), 2006-2011 21
Table 9: Myasthenia Gravis Therapeutics Market, France, Forecasts ($m), 2011-2019 22
Table 10: Myasthenia Gravis Therapeutics Market, Germany, Revenue ($m), 2006-2011 23
Table 11: Myasthenia Gravis Therapeutics Market, Germany, Forecasts ($m), 2011-2019 24
Table 12: Myasthenia Gravis Therapeutics Market, Italy, Revenue ($m), 2006-2011 25
Table 13: Myasthenia Gravis Therapeutics Market, Italy, Forecasts ($m), 2011-2019 26
Table 14: Myasthenia Gravis Therapeutics Market, Spain, Revenue ($m), 2006-2011 27
Table 15: Myasthenia Gravis Therapeutics Market, Spain, Forecasts ($m), 2011-2019 28
Table 16: Myasthenia Gravis Therapeutics Market, The UK, Revenue ($m), 2006-2011 29
Table 17: Myasthenia Gravis Therapeutics Market, The UK, Forecasts ($m), 2011-2019 30
Table 18: Myasthenia Gravis Therapeutics Market, Japan, Revenue ($m), 2006-2011 31
Table 19: Myasthenia Gravis Therapeutics Market, Japan, Forecasts ($m), 2011-2019 32
Table 20: Myasthenia gravis Therapeutics, Phase III Pipeline, 2011 41
Table 21: Myasthenia gravis Therapeutics, Phase II Pipeline, 2011 42
Table 22: Myasthenia Gravis Therapeutics, IND Filed Pipeline, 2011 42
Table 23: Myasthenia Gravis Therapeutics, Clinical Trials by Country, 2011 46
Table 24: Myasthenia Gravis Therapeutics, Clinical Trials by Phase, 2011 47
Table 25: Myasthenia Gravis Therapeutics, Clinical Trials by Status, 2011 48
Table 26: Myasthenia Gravis Therapeutics, Prominent Sponsors, 2011 50
Table 27: Myasthenia Gravis Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 51
Table 28: Cytokinetics, Inc., Pipeline, 2011 54
Table 29: Alexion Pharmaceuticals, Inc., Pipeline, 2011 55

List of Figures

Figure 1: Normal Neuromuscular Junction 10
Figure 2: Difference Between Normal and Myasthenic Neuromuscular Junctions 11
Figure 3: Signs and Symptoms 12
Figure 4: Repetitive Nerve Stimulation Electrical Tracing 13
Figure 5: Referral Pathway 15
Figure 6: Myasthenia Gravis Therapeutics Market, Global, Revenue ($m), 2006-2011 17
Figure 7: Myasthenia Gravis Therapeutics Market, Global, Forecast ($m), 2011-2019 18
Figure 8: Myasthenia Gravis Therapeutics Market, The US, Forecast ($m), 2006-2011 19
Figure 9: Myasthenia Gravis Therapeutics Market, The US, Forecast ($m), 2011-2019 20
Figure 10: Myasthenia Gravis Therapeutics Market, France, Revenue ($m), 2006-2011 21
Figure 11: Myasthenia Gravis Therapeutics Market, France, Forecast ($m), 2011-2019 22
Figure 12: Myasthenia Gravis Therapeutics Market, Germany, Revenue ($m), 2006-2011 23
Figure 13: Myasthenia Gravis Therapeutics Market, Germany, Forecast ($m), 2011-2019 24
Figure 14: Myasthenia Gravis Therapeutics Market, Italy, Revenue ($m), 2006-2011 25
Figure 15: Myasthenia Gravis Therapeutics Market, Italy, Forecast ($m), 2011-2019 26
Figure 16: Myasthenia Gravis Therapeutics Market, Spain, Revenue ($m), 2006-2011 27
Figure 17: Myasthenia Gravis Therapeutics Market, Spain, Forecast ($m), 2011-2019 28
Figure 18: Myasthenia Gravis Therapeutics Market, The UK, Revenue ($m), 2006-2011 29
Figure 19: Myasthenia Gravis Therapeutics Market, The UK, Forecast ($m), 2011-2019 30
Figure 20: Myasthenia Gravis Therapeutics Market, Japan, Revenue ($m), 2006-2011 31
Figure 21: Myasthenia Gravis Therapeutics Market, Japan, Forecast ($m), 2011-2019 32
Figure 22: Opportunity and Unmet Need in the Myasthenia Gravis Therapeutics Market, 2011 34
Figure 23: Myasthenia Gravis Therapeutics, Strategic Competitor Assessment, 2010 36
Figure 24: Myasthenia gravis Therapeutics - Pipeline by Phase of Development, 2011 41
Figure 25: Myasthenia Gravis Therapeutics, Technology Trends Analytics Framework, 2011 43
Figure 26: Myasthenia Gravis Pipeline, Technology Trends Analytics Framework, Description, 2011 43
Figure 27: Myasthenia Gravis Therapeutics, Pipeline by Mechanism of Action, 2011 44
Figure 28: Myasthenia Gravis Therapeutics, Clinical Trials by Country, 2011 46
Figure 29: Myasthenia Gravis Therapeutics, Clinical Trials by Phase (%), 2011 47
Figure 30: Myasthenia Gravis Therapeutics, Clinical Trials by Status (%), 2011 48
Figure 31: Myasthenia Gravis Therapeutics, Overall Sponsors (%), 2011 49
Figure 32: Myasthenia Gravis Therapeutics, Prominent Sponsors (%), 2011 50
Figure 33: Myasthenia Gravis Therapeutics Market, Drivers and Restraints, 2011 52
Figure 34: Implications for Future Market Competition in the Myasthenia Gravis Therapeutics Market, 2011 53
Figure 35: GlobalData Market Forecasting Model 60